BUZZ-Gilead, cancer test makers up after U.S. top court ruling on preventative coverage

Reuters
06/27
BUZZ-Gilead, cancer test makers up after U.S. top court ruling on preventative coverage

** Shares of Gilead Sciences GILD.O rise 3.1% to $110.69 in morning trade

** U.S. Supreme Court rules in favor of Obamacare preventive care task force

** The task force helps guarantee that health insurers cover preventive care such as cancer screenings at no cost to patients

** Cancer test makers such as Exact Sciences EXAS.O up 4.8% at $54.32 and Guardant Health GH.O up 1.6%

** Labcorp Holdings LH.N, which offers cancer tests, is up 1.5% at $260.73

** The justices in a 6-3 decision reversed the lower court's ruling on Friday which will likely help in allaying investor fears on insurance coverage for PrEP or pre-exposure prophylaxis drugs

** PrEP drugs are approved in the U.S. to prevent HIV infection which are made by Gilead and by ViiV Healthcare, a joint venture of GSK GSK.L, Pfizer PFE.N and Shionogi 4507.T

** Including session's move, GILD up 17.3%, EXAS down 3.9%, LH up 13.5%, GH up 65% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10